The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 470.00
Bid: 450.00
Ask: 490.00
Change: 10.00 (2.17%)
Spread: 40.00 (8.889%)
Open: 460.00
High: 470.00
Low: 460.00
Prev. Close: 460.00
SYS1 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

12 Apr 2023 07:00

RNS Number : 8896V
System1 Group PLC
12 April 2023
 

 

 

12 April 2023

 

 

System1 Group PLC (AIM: SYS1)

 ("System1", or "the Company", or "the Group")

 

Final Quarter Trading Update

 

 

System1 today issues an update on trading for the quarter ended 31 March 2023 (Q4).

 

 

FY23

Revenue £ million - unaudited *

Q1

Q2

H1

Q3

Q4

H2

FY

Jun-22

Sep-22

Dec-22

Mar-23

Mar-23

Predict Your (data)

2,964

3,189

6,153

3,400

4,107

7,507

13,660

Improve Your (data-led consultancy)

752

694

1,446

862

1,163

2,025

3,471

Standard (platform revenue)

3,716

3,883

7,599

4,262

5,270

9,532

17,131

Other consultancy (non-platform)

1,529

1,368

2,897

1,964

1,354

3,318

6,215

Total Revenue

5,245

5,251

10,496

6,226

6,624

12,850

23,346

 

 * The Company has disclosed additional information in relation to the breakdown of revenues, which it intends to provide going forward. All numbers in this announcement are unaudited and therefore may be subject to change.

 

During Q4, the Company made substantial and measurable progress towards the strategic objectives that the board set out following the strategic review, specifically growing our standard Predict Your and Improve Your products (platform-based data and consultancy) to a point where they represented 80% of revenue in Q4.

Predict Your (data) revenue grew by 67% on the comparable prior-year quarter to £4.1m, a quarterly record, and by 40% for the financial year to £13.7m. Improve Your (data-led consultancy) revenue increased by 95% over the comparable prior-year quarter and by 29% for the financial year overall. Standard product revenues therefore grew by 73% on Q4 FY22 and by 38% for the financial year and represented 80% of revenues in Q4 and 73% for the financial year.

For the year as a whole, Other Consultancy (non-platform) revenue was £5.5m lower at £6.2m. In H2 Other Consultancy revenue grew on H1, following three successive periods of half-on-half reduction, reinforcing the Board's belief that the decline in non-strategic revenue is substantially behind us.

Total Group revenue rose by 26% in Q4 and 9% in H2 ending the year at £23.3m, 3% lower than FY22 (standard platform revenue +38%, Other non-platform consultancy -47%).

Excellent progress was made in the US in Q4 where we won new mandates from 3 of the country's 25 biggest advertising spenders, including the largest. The US delivered its highest half year of revenue since FY21, and standard product revenue increased by 23% for the year as a whole.

 

Following the launch of Test Your Idea, Innovation product revenue increased by 28% in H2 versus H1. Communications products, primarily Test Your Ad, continued to grow by over 20% H2 on H1. Brand grew by 12% year on year, helped by the first full year of Test Your Brand.

 

The improved revenue performance in H2 is expected to bring a return to profitability at adjusted and statutory levels for H2 and also for the year as a whole, based on the unaudited management accounts, and the Board now anticipates that profit for the year ended 31 March 2023 will slightly exceed its previous expectations. As indicated in the 23 February 2023 trading update, there was a cash inflow during Q4, resulting in year-end net cash of £5.7m.

 

Commenting on the results, CEO James Gregory said: "I am delighted with the upturn in performance in the second half-year. The profitable growth in our standard, platform-based products in the US and elsewhere demonstrates that we have the right strategy, business model and management team."

 

General Meeting 21 April

The company has called a general meeting for 21 April 2023 to consider four resolutions proposed by shareholders Stefan Barden and James Geddes ("Requisitioning Shareholders"). The Board believes that the latest quarter's trading performance demonstrates that the company's product and go-to-market strategy is correct, and that management is executing the plan effectively. We repeat our recommendation in the Circular dated 24 March 2023 that the Board considers that all the resolutions proposed by the Requisitioning Shareholders are not in the best interest of the Company and the shareholders as a whole, and that the Board will be voting against all of them and unanimously recommends that shareholders do the same.

 

Further information on the Company can be found at www.system1group.com.

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

For further information, please contact:

System1 Group PLC

Tel: +44 (0)20 7043 1000

James Gregory, Chief Executive Officer

Chris Willford, Chief Financial Officer

Canaccord Genuity Limited (Nominated Adviser & Broker)

Tel: +44 (0)20 7523 8000

 

Simon Bridges / Andrew Potts

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKDBQCBKDKQD
Date   Source Headline
16th Apr 20247:00 amRNSTrading Update
24th Jan 20247:00 amRNSTrading Update
12th Dec 202312:51 pmRNSPresentation via Investor Meet Company
6th Dec 20237:00 amRNSChange of Auditor
6th Dec 20237:00 amRNSInterim Results
24th Oct 20237:00 amRNSTrading Update
27th Sep 20236:00 pmRNSResult of AGM
27th Sep 20237:00 amRNSTrading Update
31st Aug 20237:00 amRNSAnnual Report and Notice of AGM
1st Aug 20237:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2023
31st Jul 20232:00 pmRNSPreliminary Results Presentation
13th Jul 20237:30 amRNSTrading update
30th Jun 20239:00 amRNSResolution of Complaint for Trademark Infringement
28th Jun 202311:00 amRNSHolding(s) in Company
3rd May 20233:15 pmRNSFurther re Result of General Meeting
21st Apr 202311:56 amRNSResult of General Meeting
13th Apr 20237:00 amRNSFurther re Requisitioned General Meeting
12th Apr 20237:00 amRNSTrading Update
5th Apr 202310:45 amRNSNotice of Trading Update
24th Mar 20234:00 pmRNSPosting of Circular and Notice of Requisitioned GM
24th Mar 20237:00 amRNSPosting of Circular and Notice of Requisitioned GM
7th Mar 20237:30 amRNSReceipt of Requisition Notice
28th Feb 202312:50 pmRNSCapital Markets Day
23rd Feb 20237:00 amRNSTrading Update
14th Feb 20237:00 amRNSCapital Markets Day
13th Jan 20232:00 pmRNSDirector/PDMR Shareholding
10th Jan 202310:30 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 20224:00 pmRNSDirector/PDMR Shareholding
13th Dec 20226:25 pmRNSDirector/PDMR Shareholding
6th Dec 20224:15 pmRNSDirectorate Change
30th Nov 20227:00 amRNSInterim Results
25th Oct 20227:00 amRNSTrading Update
28th Sep 20226:15 pmRNSResult of AGM
31st Aug 202211:00 amRNSNotice of AGM
31st Aug 20227:00 amRNSDirectorate Change
31st Aug 20227:00 amRNSReview of strategic options
30th Aug 20226:00 pmRNSTransaction in Own Shares
19th Aug 20228:55 amRNSTransaction in Own Shares
3rd Aug 20225:45 pmRNSTransaction in Own Shares
2nd Aug 20223:45 pmRNSTransaction in Own Shares
29th Jul 20229:30 amRNSTransaction in Own Shares
26th Jul 20226:24 pmRNSTransaction in Own Shares
19th Jul 20224:00 pmRNSHolding(s) in Company
19th Jul 20223:00 pmRNSTransaction in Own Shares
18th Jul 20224:30 pmRNSTransaction in Own Shares
15th Jul 20225:15 pmRNSTransaction in Own Shares
12th Jul 20227:00 amRNSShare Buyback Programme
12th Jul 20227:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2022
12th Jul 20227:00 amRNSQuarterly Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.